The Prevalence Survey of ALDH Gene Family in Patients With Peripheral Arterial Occlusive Disease or Acute Coronary Syndrome

NCT05078814 | Recruiting

• 1 other identifier: CMMC10705-003
• Study Type: observational
• Target: 600
• Locations: 1 country
• Sites: 1

Brief Summary

Aldehyde dehydrogenase 2 (ALDH2) is an important enzyme protecting human from the accumulation of aldehyde, the main metabolites of alcohol. The deficiency of ALDH2 gene results in flush and hang over post drinking and most importantly it has been found associated with the incidence of cancer and post myocardial infarction (MI) heart failure. In the previous studies, ALDH2 decreased the ischemic territory post infarction and using a large scaled interaction of genetic variants and ALDH2 as an instrument, the threats of alcohol consumption on Asians' cardiovascular health was underscored. Furthermore, in a meta-analysis reviewing 12 case-control studies also indicated an increase of 48% risks in patients with ALDH2 deficiency. Notably, the genetic deficiency is most prevalent in Asians. In Taiwan one of every two individuals may be the victim and the high prevalence is counted as the top of the world. However, a large scaled prospective study focusing on the prevalence of ALDH2 deficiency in patients with peripheral artery occlusive disease (PAOD) or acute coronary syndrome （ACS）remains lacking.

Conditions

Peripheral Artery Occlusive Disease; Acute Coronary Syndrome

Keywords

Peripheral Artery Occlusive Disease or Acute Coronary Syndrome

Outcome Measures

Primary Outcomes (1)

• The incidence of MALE(major adverse limb events) in peripheral arterial disease and acute coronary disease.

  2 years

Secondary Outcomes (1)

• The incidence of MACCE(major adverse cardiac and cerebrovascular events) in peripheral arterial disease and acute coronary disease.

  2 years

Interventions

Observational research OTHER

Observational research

Eligibility Criteria

• Age: 20 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Diagnosed as peripheral arterial obstruction or acute coronary syndrome.

You may qualify if:

• Age≧20 y/o
• Using ankle-brachial index (ABI)\< 0.9, angiography, vascular duplex, CAT scan or cardiologists'impression to confirm the diagnosis of PAOD
• Clinical presentation of claudication
• diagnosis of ACS

You may not qualify if:

• If the patient refuses to be included in this study

Sponsors & Collaborators

• Chimei Medical Center: lead

Study Sites (1)

Wei-Ting Chang

Tainan, Taiwan

RECRUITING

MeSH Terms

Conditions

Peripheral Arterial Occlusive Disease 1; Acute Coronary Syndrome

Condition Hierarchy (Ancestors)

Myocardial Ischemia; Heart Diseases; Cardiovascular Diseases; Vascular Diseases

Central Study Contacts

Wei-Ting Chang

CONTACT

+886-6-2812811; cmcvecho2@gmail.com

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: PROSPECTIVE
• Target Duration: 2 Years
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Doctor of Medicine

Study Record Dates

• First Submitted: September 6, 2021
• First Posted: October 15, 2021
• Study Start: March 1, 2018
• Primary Completion (Estimated): December 31, 2026
• Study Completion (Estimated): December 31, 2026
• Last Updated: October 15, 2021

Record last verified: 2021-09

Data Sharing

• IPD Sharing: Will not share

Locations

TW (1)